The global rare disease genetic testing market size is expected to reach USD 1.8 Billion by 2027

Global Rare Disease Genetic Testing Market Size study, by Type (Neurological Disorders, Immunological Disorders, Hematology Diseases, Endocrine & Metabolism Diseases, Cancer, Musculoskeletal Disorders, Cardiovascular Disorders, Dermatology Diseases, Other Rare Diseases) Technology (Next Generation Sequencing, Array Technology, PCR - based Testing, FISH, Sanger Sequencing, Karyotyping) Specialty (Molecular Genetic Tests ,Chromosomal Genetic Tests ,Biochemical Genetic Tests) End-use (Research Laboratories & CROs, Hospitals & Clinics, Diagnostic Laboratories)and Regional Forecasts 2021-2027
Product Code:  HALB_49827874
Chapter 1.Executive Summary 
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2027 (USD Billion)
1.2.1. Rare Disease Generic Testing Market , by Region, 2019-2027 (USD Billion)
1.2.2. Rare Disease Generic Testing Market , by Disease Type, 2019-2027 (USD Billion)
1.2.3. Rare Disease Generic Testing Market , by Technology Outlook, 2019-2027 (USD Billion)
1.2.4. Rare Disease Generic Testing Market , by Speciality Outlook, 2019-2027 (USD Billion)
1.2.5. Rare Disease Generic Testing Market , by End use Outlook, 2019-2027 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Rare Disease Generic Testing Market Definition and Scope 
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Rare Disease Generic Testing Market Dynamics 
3.1. Rare Disease Generic Testing Market  Impact Analysis (2019-2027)
3.1.1. Market Drivers
3.1.1.1. The need for an accurate and timely diagnosis for rare conditions 
3.1.2. Market Challenges
3.1.2.1. Lack of awareness about the diseases and its  underlying effects
3.1.3. Market Opportunities
3.1.3.1. Technological advancements in data collection and interpretation for clinical practice
Chapter 4. Global Rare Disease Generic Testing Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model (2018-2027)
4.2. PEST Analysis
4.2.1. Political 
4.2.2. Economical
4.2.3. Social 
4.2.4. Technological 
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global Rare Disease Generic Testing Market , by Disease Type 
5.1. Market Snapshot 
5.2. Global Rare Disease Generic Testing Market  by Disease Type, Performance - Potential Analysis
5.3. Global Rare Disease Generic Testing Market  Estimates & Forecasts by Disease Type 2018-2027 (USD Billion)
5.4. Rare Disease Generic Testing Market , Sub Segment Analysis
5.4.1.   Neurological Disorders, 
5.4.2. Immunological Disorders, 
5.4.3. Hematology Diseases, 
5.4.4. Endocrine & Metabolism Diseases, 
5.4.5. Cancer, 
5.4.6. Musculoskeletal Disorders, 
5.4.7. Cardiovascular Disorders, 
5.4.8. Dermatology Diseases, 
5.4.9. Other Rare Diseases
Chapter 6. Global Rare Disease Generic Testing Market , by Technology Outlook          
6.1. Market Snapshot 
6.2. Global Rare Disease Generic Testing Market  by Technology Outlook, Performance - Potential Analysis
6.3. Global Rare Disease Generic Testing Market  Estimates & Forecasts by Technology Outlook 2018-2027 (USD Billion)
6.4. Rare Disease Generic Testing Market , Sub Segment Analysis
6.4.1.    Next Generation Sequencing 
6.4.2. Array Technology 
6.4.3. PCR - based Testing 
6.4.4. FISH 
6.4.5. Sanger Sequencing
6.4.6. Karyotyping
Chapter 7. Global Rare Disease Generic Testing Market , by Speciality Outlook          
7.1. Market Snapshot 
7.2. Global Rare Disease Generic Testing Market  by Speciality Outlook, Performance - Potential Analysis
7.3. Global Rare Disease Generic Testing Market  Estimates & Forecasts by Speciality Outlook 2018-2027 (USD Billion)
7.4. Rare Disease Generic Testing Market , Sub Segment Analysis
7.4.1.    Molecular Genetic Tests 
7.4.2. Chromosomal Genetic Tests 
7.4.3. Biochemical Genetic Tests
Chapter 8. Global Rare Disease Generic Testing Market , by End use Outlook          
8.1. Market Snapshot 
8.2. Global Rare Disease Generic Testing Market  by End use Outlook, Performance - Potential Analysis
8.3. Global Rare Disease Generic Testing Market  Estimates & Forecasts by End use Outlook 2018-2027 (USD Billion)
8.4. Rare Disease Generic Testing Market , Sub Segment Analysis
8.4.1. Research Laboratories & CROs, 
8.4.2. Hospitals & Clinics,
8.4.3.  Diagnostic Laboratories



Chapter 9. Global Rare Disease Generic Testing Market , Regional Analysis
9.1. Rare Disease Generic Testing Market , Regional Market Snapshot 
9.2. North America Rare Disease Generic Testing Market  
9.2.1. U.S. Rare Disease Generic Testing Market 
9.2.1.1.  Disease Type breakdown estimates & forecasts, 2018-2027 
9.2.1.2.  Technology Outlook breakdown estimates & forecasts, 2018-2027 
9.2.1.3. Speciality Outlook breakdown estimates & forecasts, 2018-2027 
9.2.1.4. End Use Outlook breakdown estimates & forecasts, 2018-2027
9.2.2. Canada Rare Disease Generic Testing Market 
9.3. Europe Rare Disease Generic Testing Market  Snapshot
9.3.1. U.K. Rare Disease Generic Testing Market  
9.3.2. Germany Rare Disease Generic Testing Market 
9.3.3. France Rare Disease Generic Testing Market 
9.3.4. Spain Rare Disease Generic Testing Market 
9.3.5. Italy Rare Disease Generic Testing Market 
9.3.6. Rest of Europe Rare Disease Generic Testing Market 
9.4. Asia-Pacific Rare Disease Generic Testing Market  Snapshot
9.4.1. China Rare Disease Generic Testing Market  
9.4.2. India Rare Disease Generic Testing Market  
9.4.3. Japan Rare Disease Generic Testing Market 
9.4.4. Australia Rare Disease Generic Testing Market 
9.4.5. South Korea Rare Disease Generic Testing Market 
9.4.6. Rest of Asia Pacific Rare Disease Generic Testing Market 
9.5. Latin America Rare Disease Generic Testing Market  Snapshot
9.5.1. Brazil Rare Disease Generic Testing Market 
9.5.2. Mexico Rare Disease Generic Testing Market 
9.6. Rest of The World Rare Disease Generic Testing Market 

Chapter 10. Competitive Intelligence
10.1. Top Market Strategies
10.2. Company Profiles
10.2.1. Quest Diagnostics Inc
10.2.1.1. Key Information
10.2.1.2. Overview
10.2.1.3. Financial (Subject to Data Availability)
10.2.1.4. Product Summary
10.2.1.5. Recent Developments
10.2.2. Centogene N.V.
10.2.3. Invitae Corporation
10.2.4. 3billion, Inc.
10.2.5. Arup Laboratories
10.2.6. Eurofins Scientific
10.2.7. Strand Life Sciences
10.2.8. Ambry Genetics
10.2.9. Perkin Elmer, Inc.
10.2.10. Macrogen, Inc.
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
11.3. Research Assumption

Global Rare Disease Genetic Testing Market is valued approximately USD 0.9186 Billion in 2020 and is anticipated to grow with a healthy growth rate of more than 10.9% over the forecast period 2021-2027. Rare Disease Genetic Testing is a test which presents the range of all the genes which are currently known to cause human disease. There are about 6000 genes which reported to be clinically relevant. These genes contains a select set of genes or gene region which are suspected to have relationship with certain diseases. This lead to a rise in the number of already present genes and as a result it further increased the market growth opportunity for this sector as it allows to collect sufficient amount of data which enables to continue clinical research for future discoveries. These diseases possess a threat to the mankind and needs to be diagnosed timely and accurately. This proves to be a driving factor for the market. The lack of awareness to these conditions is a primary challenge for the market. The Misdiagnosis of the diseases can result in interventions which could later be considered inappropriate for the underlying disorder. Therefore there is an urgent need to raise awareness about the aspects of these diseases like the challenges concerning with regard to diagnosis and clinical implementation of available diagnostic ways. Along with all the above stated factors technological advancements in collection of data and interpretation for clinical practice has also driven the market. Various efforts have been made by the market players in order to collect data from different ethnicities.

The regional analysis of global Rare Disease Genetic Testing Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leader in Genetic Testing Market with an overall share of 47% of the total market in 2019.There will be a surge in the number of patients in the coming years this will further allow the market to grow. On the other hand, Asia Pacific is expected to grow more significantly in the coming years due to the increased awareness and rising populations in the Asian countries.

Major market player included in this report are:
Quest Diagnostics Inc.
Centogene N.V.
Invitae Corporation
3billion, Inc.
Arup Laboratories
Eurofins Scientific
Strand Life Sciences
Ambry Genetics
Perkin Elmer, Inc.
Macrogen, Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:Neurological Disorders
Immunological Disorders
Hematology Diseases
Endocrine & Metabolism Diseases
Cancer
Musculoskeletal Disorders
Cardiovascular Disorders
Dermatology Diseases
Other Rare Diseases
By Technology:Next Generation Sequencing
Array Technology
PCR – based Testing
FISH
Sanger Sequencing
Karyotyping
By Specialty:Molecular Genetic Tests
Chromosomal Genetic Tests
Biochemical Genetic Tests
By End-use:Research Laboratories & CROs
Hospitals & Clinics
Diagnostic Laboratories

By Region:
• North America
o U.S.
o Canada
• Europe
o UK
o Germany
o France
o Spain
o Italy
o ROE

• Asia Pacific
o China
o India
o Japan
o Australia
o South Korea
o RoAPAC
• Latin America
o Brazil
o Mexico
• Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019
Base year – 2020
Forecast period – 2021 to 2027

Target Audience of the Global Rare Disease Genetic Testing Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors


We offer 10% free customization including country-level data, niche applications and competitive landscape with every report. This also includes a 30 minute free analyst discussion post report purchase.

Full Name*

Business Email* (Please avoid generic email IDs such as gmail, yahoo)

Phone* (Please Affix Country Code)

Need specific market information? To get a customized report, please share your exact research requirements.



Loading…